文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

创新纳米药物递送:靶向肿瘤微环境以克服耐药性。

Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.

作者信息

Meng Wenjun, Huang Li, Guo Jiamin, Xin Qing, Liu Jiyan, Hu Yuzhu

机构信息

Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Pharmaceutics. 2024 Dec 3;16(12):1549. doi: 10.3390/pharmaceutics16121549.


DOI:10.3390/pharmaceutics16121549
PMID:39771528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11728492/
Abstract

Nanodrug delivery systems have revolutionized tumor therapy like never before. By overcoming the complexity of the tumor microenvironment (TME) and bypassing drug resistance mechanisms, nanotechnology has shown great potential to improve drug efficacy and reduce toxic side effects. This review examines the impact of the TME on drug resistance and recent advances in nanomedicine delivery systems to overcome this challenge. Characteristics of the TME such as hypoxia, acidity, and high interstitial pressure significantly reduce the effectiveness of chemotherapy and radiotherapy, leading to increased drug resistance in tumor cells. Then, this review summarizes innovative nanocarrier designs for these microenvironmental features, including hypoxia-sensitive nanoparticles, pH-responsive carriers, and multifunctional nanosystems that enable targeted drug release and improved drug penetration and accumulation in tumors. By combining nanotechnology with therapeutic strategies, this review offers a novel perspective by focusing on the innovative design of nanocarriers that interact with the TME, a dimension often overlooked in similar reviews. We highlight the dual role of these nanocarriers in therapeutic delivery and TME modulation, emphasize their potential to overcome drug resistance, and look at future research directions.

摘要

纳米药物递送系统彻底改变了肿瘤治疗,前所未有的变革。通过克服肿瘤微环境(TME)的复杂性并绕过耐药机制,纳米技术已显示出提高药物疗效和减少毒副作用的巨大潜力。本综述探讨了TME对耐药性的影响以及纳米医学递送系统为克服这一挑战所取得的最新进展。TME的特征,如缺氧、酸性和高间质压力,显著降低了化疗和放疗的效果,导致肿瘤细胞耐药性增加。然后,本综述总结了针对这些微环境特征的创新纳米载体设计,包括缺氧敏感纳米颗粒、pH响应载体以及能够实现靶向药物释放并改善药物在肿瘤中的渗透和积累的多功能纳米系统。通过将纳米技术与治疗策略相结合,本综述通过关注与TME相互作用的纳米载体的创新设计提供了一个新颖的视角,这是类似综述中经常被忽视的一个维度。我们强调了这些纳米载体在治疗递送和TME调节中的双重作用,强调了它们克服耐药性的潜力,并展望了未来的研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/21ce9c7f4a63/pharmaceutics-16-01549-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/c14b92958462/pharmaceutics-16-01549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/ad158ef289b5/pharmaceutics-16-01549-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/225f96c182ba/pharmaceutics-16-01549-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/33a494d48b42/pharmaceutics-16-01549-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/159345564d8a/pharmaceutics-16-01549-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/21ce9c7f4a63/pharmaceutics-16-01549-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/c14b92958462/pharmaceutics-16-01549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/ad158ef289b5/pharmaceutics-16-01549-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/225f96c182ba/pharmaceutics-16-01549-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/33a494d48b42/pharmaceutics-16-01549-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/159345564d8a/pharmaceutics-16-01549-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3163/11728492/21ce9c7f4a63/pharmaceutics-16-01549-g006.jpg

相似文献

[1]
Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.

Pharmaceutics. 2024-12-3

[2]
Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.

Curr Med Chem. 2023

[3]
T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.

J Immunother Cancer. 2023-2

[4]
Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC.

Int J Nanomedicine. 2025-3-17

[5]
Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies.

Pharmaceutics. 2025-4-11

[6]
Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.

Cancer Metastasis Rev. 2023-9

[7]
Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023-1

[8]
Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.

Acc Chem Res. 2018-10-15

[9]
Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer.

Mol Pharm. 2024-12-2

[10]
Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy.

Expert Opin Drug Deliv. 2023

引用本文的文献

[1]
The malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: microenvironment-mediated drug resistance and therapeutic targets.

Front Immunol. 2025-8-20

[2]
Cell-in-cell associated lncRNA signature predicts prognosis and immunotherapy response in gastric cancer.

Front Oncol. 2025-7-8

[3]
Circadian-Tuned Peptide Drug/Gene Co-Delivery Nanocomplexes to Enhance Glioblastoma Targeting and Transfection.

Int J Mol Sci. 2025-6-26

[4]
Molecular markers for the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma.

Front Oncol. 2025-6-23

[5]
Effective imaging examination evaluation method for surgical pathological complete responds of head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy.

Front Oncol. 2025-6-10

[6]
Heterogenous cancer-associated fibroblasts related tumor microenvironment marked by CD10/KLF4/TIAM1 were identified in pancreatic adenocarcinoma by integrated transcriptomics.

Front Immunol. 2025-4-14

本文引用的文献

[1]
Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment.

Small. 2025-1

[2]
Sintilimab Combined with Nanoparticle Albumin-Bound Paclitaxel-Based Chemotherapy in Severe Locally Advanced or Metastatic Squamous NSCLC Showed Good Efficacy and Safety: A Pilot Retrospective Analysis.

Int J Nanomedicine. 2024

[3]
Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant cancer.

Acta Pharm Sin B. 2024-10

[4]
Protein arginine methyltransferase 5 confers the resistance of triple-negative breast cancer to nanoparticle albumin-bound paclitaxel by enhancing autophagy through the dimethylation of ULK1.

Toxicol Appl Pharmacol. 2024-12

[5]
Photothermally Reinforced Nanozyme Remodeling Tumor Microenvironment of Redox and Metabolic Homeostasis to Enhance Ferroptosis in Tumor Therapy.

ACS Nano. 2024-11-19

[6]
Omics-Enhanced Nanomedicine for Cancer Therapy.

Adv Mater. 2024-12

[7]
Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study.

BMC Med. 2024-10-29

[8]
Reprogramming-based gene therapy promotes anti-tumor immunity in vivo.

Nat Genet. 2024-10

[9]
Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.

J Nanobiotechnology. 2024-10-6

[10]
An insight into impact of nanomaterials toxicity on human health.

PeerJ. 2024

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索